Davenport & Co’s Axsome Therapeutics AXSM Stock Holding History

Davenport & Co’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$441K	Hold	1,800	–	–	﹤0.01%	1066
2026 Q1	$304K	Hold	1,800	–	–	﹤0.01%	1126
2025 Q4	$329K	Sell	1,800 -67	-4%	-$9.35K	﹤0.01%	1053
2025 Q3	$227K	Buy	+1,867	New	+$210K	﹤0.01%	1167
2025 Q2	–	Sell	-1,867	Closed	-$218K	–	1209
2025 Q1	$218K	Buy	+1,867	New	+$213K	﹤0.01%	1109
2024 Q2	–	Sell	-5,817	Closed	-$464K	–	1115
2024 Q1	$464K	Buy	5,817 +2,000	+52%	+$168K	﹤0.01%	833
2023 Q4	$304K	Buy	+3,817	New	+$255K	﹤0.01%	907
2023 Q1	–	Sell	-14,200	Closed	-$1.09M	–	1045
2022 Q4	$1.09M	Buy	+14,200	New	+$849K	0.01%	484
2020 Q1	–	Sell	-2,300	Closed	-$238K	–	669
2019 Q4	$238K	Buy	+2,300	New	+$92.9K	﹤0.01%	636

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Davenport & Co's AXSM Position: Q2 2026 in Review

Davenport & Co held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 1,800 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

Davenport & Co first reported a position in AXSM in Q4 2019 and has held it in 9 quarters since. The position peaked at $1.09M in Q4 2022. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Davenport & Co held 1,800 shares of Axsome Therapeutics worth $441K as of Q2 2026.
Davenport & Co left its Axsome Therapeutics share count unchanged in Q2 2026.
Axsome Therapeutics made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #1066 holding.
Davenport & Co first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 9 quarters since.
Davenport & Co's Axsome Therapeutics position peaked at $1.09M in Q4 2022.
38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.